Androgen receptor (AR) action is a hallmark of prostate cancer (PCa) with androgen deprivation being standard therapy. Yet, resistance arises and aberrant AR signaling promotes disease. We sought compounds that inhibited genes driving cancer but not normal growth and hypothesized that genes with consensus androgen response elements (cAREs) drive proliferation but genes with selective elements (sAREs) promote differentiation. In a high-throughput promoter-dependent drug screen, doxorubicin (dox) exhibited this ability, acting on DNA rather than AR. This dox effect was observed at low doses for multiple AR target genes in multiple PCa cell lines and also occurred in vivo. Transcriptomic analyses revealed that low dox downregulated cell cycle genes while high dox upregulated DNA damage response genes. In chromatin immunoprecipitation (ChIP) assays with low dox, AR binding to sARE-containing enhancers increased, whereas AR was lost from cAREs. Further, ChIP-seq analysis revealed a subset of genes for which AR binding in low dox increased at pre-existing sites that included sites for prostate-specific factors such as FOXA1. AR dependence on cofactors at sAREs may be the basis for differential modulation by dox that preserves expression of genes for survival but not cancer progression. Repurposing of dox may provide unique opportunities for PCa treatment.
© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.
Androgen receptor genomic regulation.Version 2. Transl Androl Urol. 2013 Sep;2(3):157-177. doi: 10.3978/j.issn.2223-4683.2013.09.01. Transl Androl Urol. 2013. PMID: 25237629 Free PMC article.
Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.Prostate. 2015 Sep;75(13):1363-75. doi: 10.1002/pros.23017. Epub 2015 May 27. Prostate. 2015. PMID: 26015225
Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells.Oncogene. 2011 Feb 3;30(5):619-30. doi: 10.1038/onc.2010.436. Epub 2010 Oct 4. Oncogene. 2011. PMID: 20890304
Androgen action in the prostate gland.Minerva Urol Nefrol. 2012 Mar;64(1):35-49. Minerva Urol Nefrol. 2012. PMID: 22402316 Review.
Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers.Endocr Relat Cancer. 2019 May;26(5):R267-R285. doi: 10.1530/ERC-19-0032. Endocr Relat Cancer. 2019. PMID: 30865928 Review.